Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aficamten QT/QTc Study in Healthy Participants
NCT05924815Phase 1Completed
- Sponsor
- Cytokinetics
- Start
- May 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aficamten in hypertrophic cardiomyopathy (HCM) (6 arms), sponsored by Cytokinetics. Primary endpoints: Dose determination for Part B at 8 weeks and Placebo-corrected change from baseline in QTcF at 14.5 weeks. Started May 2023; status: completed.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT05924815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05924815.